FOLH1 and prostate carcinoma: The NP encapsulated docetaxel, a chemotherapeutic drug efficient against prostate cancer, and was functionalized with a small molecule ligand targeting the extracellular domain of prostate-specific membrane antigen (PSMA) that is upregulated on prostate cancer cell surfaces as well as the neovasculature of all major solid tumors (Von Hoff et al., 2016).